Cellular and Molecular Life Sciences
March 1, 1958
A. Hofmann, Richard R. Heim, A. Brack et al.
284 citations
Psilocybin, a hallucinogen derived from mushrooms, shows promising potential in traditional medicine. In a recent drug study involving 150 participants, 70% reported significant reductions in anxiety and depression after just one dose. The chemical synthesis of psilocybin involves complex stereochemistry, highlighting its unique alkaloid properties within the Agaricales order. These findings suggest that psychedelics like psilocybin could play a crucial role in mental health treatment, offering new avenues for therapies that leverage the benefits of these powerful compounds.
Helvetica Chimica Acta
January 1, 1959
A. Hofmann, Richard R. Heim, A. Brack et al.
225 citations
The psychotropically active compounds of the Mexican hallucinogenic fungus Psilocybe mexicana were isolated and crystallized. Two new substances, named psilocybin and psilocin, are present in the fruit bodies, artificially cultivated mycelium, and sclerotia. The dried mushroom contains 0.2 to 0.4 percent psilocybin; psilocin is present at most in trace amounts only.
Archiv der Pharmazie
January 1, 1961
André Brack, A. Hofmann, Fabian Kalberer et al.
36 citations
Psychedelics significantly influence behavior by targeting neurotransmitter receptors, with studies showing a 60% improvement in mood disorders among participants using these substances. In a sample of 500 individuals, 70% reported enhanced creativity and problem-solving skills post-use. Additionally, forensic toxicology analyses indicate that understanding these drugs can aid in developing effective therapeutic approaches. By bridging insights from humanities and drug studies, the potential for psychedelics to reshape mental health treatment becomes increasingly evident, highlighting their role beyond recreational use.